Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences |
| |
| Affiliation: | 1. Tumor Cell Biology Unit - Core Research Laboratory, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy;2. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;3. Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy;4. Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland |
| |
| Abstract: | The DNA damage response (DDR) is a well-coordinated cellular network activated by DNA damage. The unravelling of the key players in DDR, their specific inactivation in different tumor types and the synthesis of specific chemical inhibitors of DDR represent a new hot topic in cancer therapy. In this article, we will review the importance of DDR in lymphoma development and how this can be exploited therapeutically. Specifically, we will focus on CHK1, WEE1, ATR, DNA-PK and PARP inhibitors, for which preclinical data as single agents or in combination has been accumulating, fostering their clinical development. The few available clinical data on these inhibitors will also be discussed. |
| |
| Keywords: | DNA damage response ATR PARP ATM CHK1 WEE1 LYMPHOMA DNA-PK |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
